Transcranial magnetic stimulation measured cortical inhibition provides insight into interindividual differences in progressive myoclonic epilepsy
In patients with progressive myoclonic epilepsy type 1 (EPM1), abnormality of intracortical inhibition measured by transcranial magnetic stimulation (TMS) is associated with the magnitude of the genetic change, a new study shows. According to the researchers, TMS could prove useful in assessing patient prognosis. The study was undertaken at Kuopio University Hospital, the University of Eastern Finland, Chalfont Centre for Epilepsy in London and University College London, and the results were published in Epilepsia. EPM1 (also known as Unverricht-Lundborg disease) is a rare, severe